SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PROTEOMICS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (262)5/31/2001 7:19:06 AM
From: nigel bates   of 539
 
HEIDELBERG, Germany, May 31 /PRNewswire/ -- Graffinity Pharmaceutical Design, today announced a drug discovery alliance with Aventis Pharma. Financial terms were not disclosed.
Under the agreement, Graffinity will use its proprietary chemical micro-array based discovery platform for identification of novel lead structures for Aventis targets.
CEO of Graffinity Dr. Dirk Vetter commented: ``Graffinity's technologies are aimed at the rapid and cost effective discovery of new chemical entities, a step beyond high throughput screening. We start with a target gene and move through protein expression, screening on chemical microarrays and our proprietary RAISE technology (Rapid Array Informed Structure Evolution) to explore unprecedented chemical space and create potentially high value lead compounds.
``We are delighted to be working with a company of the calibre of Aventis Pharma and that the potential value of our unique approach to drug discovery has been recognised.''
Graffinity is a German biotech company based in Heidelberg that has taken an innovative approach to drug discovery which will significantly speed up the identification of lead structures. Graffinity's technology platform integrates chemical microarrays and a novel label-free methodology which allows the standardised analysis of proteins with numerous small organic molecules. During the RAISE process molecules are further developed to interact selectively and with high affinity with the target protein. Graffinity is looking for long-term partnerships with pharmaceutical, biotech and agrochemical companies exploiting the full potential of its lead generating platform.
For further information on Graffinity go to www.graffinity.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News